Proactive Investors - Run By Investors For Investors

ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial
The first trial data will emerge early next year - the drug's safety record has been consistently robust

ImmuPharma PLC (LON:IMM) said more than 90% of the patients on its phase III clinical study of Lupuzor, for the autoimmune disease lupus, six months through the process.

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.

A total of 46 patients, or just under a quarter, have completed the year-long assessment, while 40% have passed nine-months.

ImmuPharma said it remains on track to provide top-line results in the first quarter of next year.

The data was provided ahead of an investor update to be held in London that will be coupled with the company’s annual meeting later Friday.

“As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time,” chairman Tim McCarthy said

Big potential market

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.

It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.

ImmuPharma does not claim Lupuzor is a cure but hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.

It also thought to be more effective than other products available, such as Glaxo's Benlysta. 
View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

tablets and pills
Tue
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use